VisiPlate : a nanoscale implant for the treatment of glaucoma.
Open-angle glaucoma (OAG) is the second leading cause of blindness in the world and leads to vision loss that cannot be cured or reversed. By 2020, OAG will affect 3.4 million people in the U.S. and 80 million people globally. In OAG patients, excess fluid builds up inside the eye, putting pressure on and permanently damaging the optic nerve -- leading to blindness. Current medications, surgeries, and implants have proven inadequate in lowering pressure within the eye or sustaining normal eye pressure over many years. Consequently, there remains a pressing need for an efficacious, permanent solution.